ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

@inproceedings{Harrington2015ACP196IA,
  title={ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity},
  author={Bonnie K Harrington and Michael Gulrajani and Todd Covey and Allard Kaptein and Bart S. van Lith and Raquel Izumi and A Ziedan Hamdy and Roger S. Ulrich and John C. Byrd and Brian J. Lannutti and Amy J. Johnson},
  year={2015}
}
Background: Signaling through the B-cell receptor (BCR) results in cell survival and proliferation, and this pathway is critical for the progression of many B-cell malignancies, such a chronic lymphocytic leukemia (CLL). BTK, a TEC family kinase, is essential to the BCR signaling cascade. The recent approval of the first-in-class BTK inhibitor for the treatment certain B-cell malignancies, ibrutinib, has validated BTK as a clinical target. ACP-196 is a novel, second generation inhibitor of BTK… CONTINUE READING

Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

Acalabrutinib: First Global Approval

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Future therapeutic options for patients with Waldenström macroglobulinemia.

  • Best practice & research. Clinical haematology
  • 2016
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.

  • Expert opinion on therapeutic patents
  • 2017
VIEW 1 EXCERPT

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

  • Journal of Hematology & Oncology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND